Morepen Laboratories Ltd

MOREPENLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,368 cr, stock is ranked 683
High RiskStock is 4.01x as volatile as Nifty
57.755.10 (+9.69%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,368 cr, stock is ranked 683
High RiskStock is 4.01x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
24.39
PB RatioPB Ratio
5.58
Dividend YieldDiv. Yield
Sector PESector PE
38.20
Sector PBSector PB
5.09
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Morepen Laboratories Limited is a pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC).

Investor PresentationView older 

Nov 11, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20182019202020210.610.770.861.200.030.030.030.10
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnDec 3, 2021

Morepen Laboratories Limited has informed the Exchange regarding a press release dated December 03, 2021, titled "Morepen gets US FDA Approval for Fexofinadine (Allegra) Expected to start export in Q4 FY22". | Download

Morepen Laboratories Limited has informed the Exchange regarding a press release dated December 03, 2021, titled "Morepen gets US FDA Approval for Fexofinadine (Allegra) Expected to start export in Q4 FY22". | Download

Loss of Share Certificates 
Announced OnNov 26, 2021

Morepen Laboratories Limited has informed the Exchange about Loss of Share Certificates | Download

Morepen Laboratories Limited has informed the Exchange about Loss of Share Certificates | Download

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnNov 18, 2021

Morepen Laboratories Limited has informed the Exchange about Transcript | Download

Morepen Laboratories Limited has informed the Exchange about Transcript | Download

See all events